基本情報
- CAS
23844-24-8- 標準SMILES
CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O- InChIKey
JSZILQVIPPROJI-UHFFFAOYSA-N- 分子式
- C22H32N2O5
- 平均分子量
- 404.5 g/mol
- 単同位体質量
- 404.23112213
概要
Benzquinamide is a monocarboxylic acid amide. It has a role as an antipsychotic agent, a sedative, a H1-receptor antagonist, a muscarinic antagonist and an antiemetic.
名称と識別子
- 優先名称
- Benzquinamide
- IUPAC
- [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate
- 現地名
- ベンズキナミド
- 英語名
- Benzquinamid
- 分子式
- C22H32N2O5
- 分子量
- 404.5
名称と別名
benzquinamidePromecon63-12-7Emete-conEmeticonBenzochinamideBenzoquinamideBenzquinamidumbenzquinamidaP-2647NSC-64375DTXSID9022657
名称をさらに表示
2-(アセチルオキシ)-N,N-ジエチル-1,3,4,6,7,11b-ヘキサヒドロ-9,10-ジメトキシ-2H-ベンゾ[a]キノリジン-3-カルボアミドベンズキナミド2-アセチルオキシ-N,N-ジエチル-1,3,4,6,7,11b-ヘキサヒドロ-9,10-ジメトキシ-2H-ベンゾ[a]キノリジン-3-カルボアミドエメチコンベンゾキナミド3-(ジエチルカルバモイル)-9,10-ジメトキシ-1H,2H,3H,4H,6H,7H,11bH-ピリド[2,1-a]イソキノリン-2-イル アセタートBZQBenzquinamidN,N-DIETHYL-1,3,4,6,7,11-BENZO(A)QUINOLIZINE-3-CARBOXAMIDE2H-Benzoaquinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-[3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] acetate
2-Hydroxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzoquinolizine acetate2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-, acetate (ester)NSC-108159NSC-1691932-Acetoxy-3-(N,N-diethylcarboxamido)-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzopyridocoline2-Acetoxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-benzo(a)quinolizineDTXCID7026572-(Acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide
物性
構造計算による物性
- XLogP
- 2.1
- 極性表面積
- 68.3 Ų
- 水素結合供与体数
- 0
- 水素結合受容体数
- 6
- 回転可能結合数
- 7
- 重原子数
- 29
- 形式電荷
- 0
- 複雑度
- 582
実験および物理化学的性質
DrugsDEA NFLIS-Drug Category -> Depressants and Tranquilizers
LogP1.7
Color/FormCRYSTALS FROM DIISOPROPYL ETHER
Solubility4.90e-01 g/L
Human DrugsPharmaceuticals
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point
130-131.5
130-131.5 °C
131 °C
Physical DescriptionSolid
Stability/Shelf LifeSTABLE UP TO 5 YR @ 25 °C & UP TO 6% RELATIVE HUMIDITY; LIGHT-SENSITIVE; STABLE IN SOLN BETWEEN PH 2 & 4 /HCL/
Other Experimental PropertiesWHITE OR PALE YELLOW CRYSTALLINE POWDER; MP: 222-230 °C; DOES NOT EXHIBIT POLYMORPHISM; PKA 5.9; 1 G IS SOL IN ABOUT 12.5 ML WATER, 4 ML ALC, & 285 ML ACETONE /HCL/
物理化学的性質
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
危険有害性情報
Regulatory Information
2H-Benzoaquinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
毒性情報
Human Toxicity Excerpts
DROWSINESS APPEARS TO BE MOST COMMON ADVERSE EFFECT. OTHER ADVERSE REACTIONS... /INCL/ DRY MOUTH, SHIVERING, SWEATING, HICCOUGHS, FLUSHING, SALIVATION, & BLURRED VISION...HYPERTENSION, HYPOTENSION, DIZZINESS, ATRIAL FIBRILLATION, & PREMATURE AURICULAR & VENTRICULAR CONTRACTIONS...INSOMNIA, RESTLESSNESS, HEADACHE... /HCL/
...ADVERSE REACTIONS REPORTED ARE AS FOLLOWS: ...EXCITEMENT, NERVOUSNESS... ANOREXIA, NAUSEA...TWITCHING, SHAKING, TREMORS, & WEAKNESS...FATIGUE, CHILLS, INCR TEMP. /HCL/
安全データ
- 毒性
- LD50 orally in rats: 990 mg/kg; i.p. in mice: 376 mg/kg (Goldenthal)
- 有毒物質データの
- 63-12-7(Hazardous Substances Data)
化学と産業
薬理情報
PharmacodynamicsBenzquinamide is an antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties.
Mechanism of Action
The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.
LIKE PHENOTHIAZINES, IT APPARENTLY INHIBITS STIMULI @ CHEMORECEPTOR TRIGGER ZONE. HOWEVER, IN CONTRAST...INCR CARDIAC OUTPUT, BLOOD PRESSURE, & RESP HAVE BEEN NOTED BOTH EXPTL & CLINICALLY WITH BENZQUINAMIDE. /HCL/
Biological Half-Life1-1.6 hours (for all formulations)
Metabolism/Metabolites
BENZQUINAMIDE YIELDS 2-ACETOXY-3-(N,N-DIETHYLCARBOXAMI DO)-1,2,3,4,6,7-HEXAHYDRO-9-HYDROXY-10-METHOXY-11BH-BENZOQUINOLIZINE & 2-ACETOXY-3-(N-ETHYLCARBOXAMIDO)-1,2,3,4,6,7-HEXAHYDRO- 9,10-DIMETHOXY-11BH-BENZOQUINOLIZINE IN MAN & DOG: WISEMAN, EH ET AL, BIOCHEM PHARMAC 13, 1421 (1964). /FROM TABLE/
BENZQUINAMIDE YIELDS 3-(N,N-DIETHYLCARBOXAMIDO)-1,2,3, 4,6,7-HEXAHYDRO-2-HYDROXY-9,10-DIMETHOXY-11BH-BENZOQUINOLIZINE IN MAN & DOG: WISEMAN, EH ET AL, BIOCHEM PHARMAC 13, 1421 (1964). /FROM TABLE/
Absorption, Distribution and ExcretionIncomplete, with 33–39% bioavailability via the capsule and suppository routes, relative to the intramuscular route.
Cellular LocationsMembrane
用途と製造
UsesMEDICATION
Methods of ManufacturingTRETTNER, US PATENT 3,053,845 (1962 TO PFIZER)
Formulations/PreparationsDOSAGE FORMS: INJECTION: 50 MG TO BE RECONSTITUTED WITH 2.2 ML STERILE WATER /HCL/
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…